Skip to main content
Evidence Snapshot

Cysteinyl leukotriene receptor 1

CHEMBL1798 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T03:14:41Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL1798
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Cysteinyl leukotriene receptor 1 as ChEMBL target CHEMBL1798, mapped to UniProt Q9Y271. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Cysteinyl leukotriene receptor 1
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL1798
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
Q9Y271
Cysteinyl leukotriene receptor 1
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Cysteinyl leukotriene receptor 1 matters

As of 2026-09-14

Cysteinyl leukotriene receptor 1 is reviewed as Cysteinyl leukotriene receptor 1 (UniProt Q9Y271); Cysteinyl leukotriene receptor 1 shows approved-linked disease relevance led by Airway obstruction. 5 more disease programs remain visible in the same review block.; 2 linked drugs keep this evidence frame grounded.; the current evidence base includes 11 approved drugs, 1164 compounds, and 84 assays, with lead potency reaching pChEMBL 10.1.

Disease context
Airway obstruction

Cysteinyl leukotriene receptor 1 shows approved-linked disease relevance led by Airway obstruction. 5 more disease programs remain visible in the same review block. 2 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include PRANLUKAST, ZAFIRLUKAST.

Start review with Airway obstruction because it currently carries approved-linked support. Linked drugs include PRANLUKAST, ZAFIRLUKAST. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Approved-linked 2 linked drugs
Activity base
Portfolio and assay base

ChEMBL currently tracks 11 approved drugs, 1164 compounds, and 84 assays for this target. The dominant activity type is IC50. CHEMBL48435 is the current potency anchor at pChEMBL 10.1.

Use CHEMBL48435 as the tractability anchor when discussing potency (pChEMBL 10.1).

Activity source · ChEMBL 36 via Core Engine
11 approved pChEMBL 10.1
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Cysteinyl leukotriene receptor 1 matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q9Y271, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why Airway obstruction is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

1164
Total Compounds
84
Total Assays
11
Approved Drugs
IC50: 1104.0, KI: 840.0, EC50: 8.0, KD: 10.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL48435
 10.1 Kd —
No preferred name
CHEMBL4280282
 10.0 Kd —
No preferred name
CHEMBL344180
 9.7 IC50 —
No preferred name
CHEMBL139757
 9.7 IC50 —
No preferred name
CHEMBL3597618
 9.7 IC50 —

Approved Drugs

Structure Compound First Approval
MONTELUKAST
CHEMBL787
 1998
MONTELUKAST SODIUM
CHEMBL1200681
 1998
ZAFIRLUKAST
CHEMBL603
 1996
PRANLUKAST
CHEMBL21333
 1995
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T03:14:41Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL1798